Diamyd Trial in Chronic Pain shows Pain Relief

Substantial and sustained reduction in pain scores were reported in the middle and high dose cohorts of Diamyd Medical’s Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain. No treatment related Serious Adverse Events have been observed in the study to date.The clinical trial report includes data from the four week observation period following one single administration of NP2, delivering Enkephalin, an opioid peptide, specifically to nerves experiencing pain from cancer. The clinical trial enrolled patients that were in chronic